

## DAFTAR PUSTAKA

- Alanazi, A., Yunusa, I., Elenizi, K., Alzarea, A.I., 2020. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: A network meta-analysis. *Lung Cancer Manag.* 10. <https://doi.org/10.2217/lmt-2020-0011>
- Arjoso, S., 2020. Atlas Tembakau Indonesia Tahun 2020. Tob. Control Support Center-Ikatan Ahli Kesehatan. Masy. Indones. 1–60.
- Arrieta, O., Catalán, R., Guzmán-Vazquez, S., Barrón, F., Lara-Mejía, L., Soto-Molina, H., Ramos-Ramírez, M., Flores-Estrada, D., De La Garza, J., 2020. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. *BMC Cancer* 20, 1–8. <https://doi.org/10.1186/s12885-020-07329-8>
- Bagiada, I.M., 2017. Optimizing Management of Specific EGFR Mutant NSCLC. *Pkb-Trigonum Sudema* 24, 1--16.
- Balatif, R., Sukma, A.A.M., 2021. Memahami Kaitan Gaya Hidup dengan Kanker: Sebagai Langkah Awal Pencegahan Kanker. *Scr. SCORE Sci. Med. J.* 3, 40–50. <https://doi.org/10.32734/scripta.v3i1.4506>
- Bouchard, L.C., Aaronson, N., Gondek, K., Cella, D., 2018. Cancer symptom response as an oncology clinical trial end point. *Expert Rev. Qual. Life Cancer Care* 3, 35–46. <https://doi.org/10.1080/23809000.2018.1483193>
- Buana, I., Harahap, D.A., 2022. Asbestos, Radon Dan Polusi Udara Sebagai Faktor Resiko Kanker Paru Pada Perempuan Bukan Perokok. *AVERROUS J. Kedokt. dan Kesehatan. Malikussaleh* 8, 1. <https://doi.org/10.29103/averrous.v8i1.7088>
- Chan, B.A., Hughes, B.G.M., 2015. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. *Transl. Lung Cancer Res.* 4, 36–54. <https://doi.org/10.3978/j.issn.2218-6751.2014.05.01>
- Chouaid, C., Luciani, L., LeLay, K., Do, P., Bennouna, J., Perol, M., Moro-Sibilot,

- D., Vergnenègre, A., de Pouvourville, G., 2017. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. *J. Thorac. Oncol.* 12, 1496–1502. <https://doi.org/10.1016/j.jtho.2017.07.013>
- Chung, C.H., 2019. EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. *Oncol. Lett.* 18, 6090–6100. <https://doi.org/10.3892/ol.2019.10942>
- Ciuleanu, T., Stelmakh, L., Cicenias, S., Miliauskas, S., Grigorescu, A.C., Hillenbach, C., Johannsdottir, H.K., Klughammer, B., Gonzalez, E.E., 2012. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. *Lancet Oncol.* 13, 300–308. [https://doi.org/10.1016/S1470-2045\(11\)70385-0](https://doi.org/10.1016/S1470-2045(11)70385-0)
- Dela Cruz, C.S., Tanoue, L.T., Matthay, R.A., 2011. Lung Cancer: Epidemiology, Etiology, and Prevention. *Clin Chest Med* 32. <https://doi.org/10.1016/j.ccm.2011.09.001>
- Dwilovianita, Y., Annisa, E., Parlaungan, B., Sihite, S., Pranata, H., Ginting, N., Keperawatan, F., Kebidanan, D., 2022. Hubungan Karakteristik Nyeri Dan Kecemasan Pasien Yang Menjalani Kemoterapi 4, 17–26.
- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., Bruno, D.S., Chang, J.Y., Chirieac, L.R., D'Amico, T.A., Dilling, T.J., 2020. NCCN Clinical Guidelines in Oncology: Non-Small Cell Lung Cancer. *Natl. Compr. Cancer Netw.* 3, 1–240.
- Finger, P.T., 2014. Cancer staging. *Clin. Ophthalmic Oncol. Basic Princ. Diagnostic Tech. Second Ed.* 69–75. [https://doi.org/10.1007/978-3-642-40489-4\\_7](https://doi.org/10.1007/978-3-642-40489-4_7)
- Globocan, 2020a. Cancer Incident in Indonesia. *Int. Agency Res. Cancer* 858, 1–2.
- Globocan, 2020b. Lung Fact Sheet. *Obs. Glob. do Câncer* 419, 1–2.
- Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., Green,

- J.A., 2021. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. *Cochrane Database Syst. Rev.* 2021. <https://doi.org/10.1002/14651858.CD010383.pub3>
- Gu, X., Zhang, Q., Chu, Y.B., Zhao, Y.Y., Zhang, Y.J., Kuo, D., Su, B., Wu, B., 2019. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. *Lung Cancer* 127, 84–89. <https://doi.org/10.1016/j.lungcan.2018.11.029>
- Handoko, J.C., Dewi, I.G.A.S.M., Mahastuti, N.M., Sriwidyani, N.P., 2022. Karakteristik Klinikopatologi dan Mutasi EGFR Pada Pasien Karsinoma Paru di Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2018-2019 11.
- Hapsari, B. devi anindita, 2021. Faktor-Faktor yang Berhubungan dengan Kejadian Kanker Payudara di RSUP DR. Wahidin Sudirohusodo Makassar.
- Harrison, P.T., Vyse, S., Huang, P.H., 2020. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. *Semin. Cancer Biol.* 61, 167–179. <https://doi.org/10.1016/j.semcancer.2019.09.015>
- Hospital, A.B., Hadiningsih, H., 2015. Analisis Besaran Biaya Obat Beberapa Penyakit Rawat Jalan dan Faktor- Faktor yang Mempengaruhi di Rs. Awal Bros Bekasi Tahun 2014. *J. Adm. Rumah Sakit Indones.* 2, 53–63. <https://doi.org/10.7454/arsi.v2i1.2188>
- Hotimah, H., 2018. Hubungan Ketepatan Obat Dengan Keberhasilan Terapi Pada Pasie Hipertensi dengan Komplikasi di RSUD dr. Soebandi Jember.
- Hsu, L.H., Chu, N.M., Kao, S.H., 2017. Estrogen, estrogen receptor and lung cancer. *Int. J. Mol. Sci.* 18, 1–17. <https://doi.org/10.3390/ijms18081713>
- Imai, H., Mori, K., Wakuda, K., Ono, A., Akamatsu, H., Shukuya, T., Taira, T., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., Endo, M., Nakajima, T., Yamamoto, N., Takahashi, T., 2015. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall

- survival in patients with extensive small cell lung cancer. *Ann. Thorac. Med.* 10, 61–66. <https://doi.org/10.4103/1817-1737.146885>
- Jg, P., Pa, J., Jc, L., Kaye, F., Lindeman, N., Boggon, T., 2009. Pages : EGFR Mutations in Lung Cancer : Correlation with Clinical Response to Gefitinib Therapy 304, 1497–1500.
- Kazaz, S.N., Öztop, İ., 2017. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in Non-Small-Cell Lung Cancer. *Turkish Thorac. J.* 18, 66–71. <https://doi.org/10.5152/TurkThoracJ.2017.16042>
- Keating, G.M., 2016. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. *Target. Oncol.* 11, 825–835. <https://doi.org/10.1007/s11523-016-0465-2>
- Kemenkes, 2016. Pedoman Nasional Pelayanan Kedokteran Kanker Paru, Kementerian Kesehatan Republik Indonesia.
- Kim, Y., Lee, S.H., Ahn, J.S., Ahn, M.J., Park, K., Sun, J.M., 2019. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. *Cancer Res. Treat.* 51, 502–509. <https://doi.org/10.4143/crt.2018.117>
- Kim, Y.J., Oremus, M., Chen, H.H., McFarlane, T., Fearon, D., Horton, S., 2021. Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. *Pharmacoeconomics* 39, 537–548. <https://doi.org/10.1007/s40273-021-01022-9>
- Koswara, T., Iriawan, J., Surya, F., 2022. *Medika Kartika : Jurnal Kedokteran dan Kesehatan.* *Med. Kartika J. Kedokt. dan Kesehat.* 5, 150–161.
- Krawczyk, P., Kowalski, D.M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., Wójcik-Superczyńska, M., Głogowski, M., Barinow-Wojewódzki, A., Milanowski, J., Krzakowski, M., 2017. Comparison of the effectiveness of

erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. *Oncol. Lett.* 13, 4433–4444. <https://doi.org/10.3892/ol.2017.5980>

Lababede, O., Meziane, M.A., 2018. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. *Oncologist* 23, 844–848. <https://doi.org/10.1634/theoncologist.2017-0659>

Li, A.R., Chitale, D., Riely, G.J., Pao, W., Miller, V.A., Zakowski, M.F., Rusch, V., Kris, M.G., Ladanyi, M., 2008. Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. *J. Mol. Diagnostics* 10, 242–248. <https://doi.org/10.2353/jmoldx.2008.070178>

Li, T., Kung, H.J., Mack, P.C., Gandara, D.R., 2013. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. *J. Clin. Oncol.* 31, 1039–1049. <https://doi.org/10.1200/JCO.2012.45.3753>

Lukeman, J.M., 2015. What Is Lung Cancer? *Perspect. Lung Cancer* 30–40. <https://doi.org/10.1159/000400400>

Lung, N.C., Radiofrequency, C., Lung, N.C., Radiation, C., Lung, N.C., Chemotherapy, C., Lung, N.C., Targeted, C., Therapy, D., Lung, N.C., Immunotherapy, C., Lung, N.C., Palliative, C., Lung, N.C., Common, C., Choices, T., Cancer, N.C.L., Who, S., n.d. *Treating Non-Small Cell Lung Cancer* 1–47.

Maione, P., Perrone, F., Gallo, C., Manzione, L., Piantodosi, F.V., Barbera, S., Cigolari, S., Rosetti, F., Piazza, E., Robbiati, S.F., Bertetto, O., Novella, S., Migliorino, M.R., Favaretto, A., Spatafora, M., Ferrà, F., Frontini, L., Bearz, A., Repetto, L., Gridelli, C., 2005. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A Prognostic analysis of the multicenter italian lung cancer in the elderly s. *J. Clin. Oncol.* 23, 6865–6872. <https://doi.org/10.1200/JCO.2005.02.527>

Manuscript, A., 2008. [The necessity for opening a specific clinical pathology from

the aspect of advancement made in nervous pathology in China.]. *Zhonghua Bing Li Xue Za Zhi* 37, 861–862. <https://doi.org/10.1016/j.ccm.2011.09.001.Lung>

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M., 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 11, 121–128. [https://doi.org/10.1016/S1470-2045\(09\)70364-X](https://doi.org/10.1016/S1470-2045(09)70364-X)

Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., Adjei, A.A., 2008. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. *Mayo Clin. Proc.* 83, 584–594. <https://doi.org/10.4065/83.5.584>

Nurhayati, F., Anggriani, Y., Syahrudin, E., Ramadaniati, H.U., Kusumaeni, T., 2021. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer. *J. Appl. Pharm. Sci.* 11, 88–95. <https://doi.org/10.7324/JAPS.2021.110411>

Perwitasari, W.A.D.A., 2021. SR (Survival Rate) 3 Tahun Pasien Kanker Paru Dengan Terapi Gefitinib Versus Erlotinib Periode 2017-2019 di RSUP Dr . Kariadi Semarang S. KA 170–181.

Pirker, R., Herth, F.J.F., Kerr, K.M., Filipits, M., Taron, M., Gandara, D., Hirsch, F.R., Grunenwald, D., Popper, H., Smit, E., Dietel, M., Marchetti, A., Manegold, C., Schirmacher, P., Thomas, M., Rosell, R., Cappuzzo, F., Stahel, R., 2010. Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop. *J. Thorac. Oncol.* 5, 1706–1713. <https://doi.org/10.1097/JTO.0b013e3181f1c8de>

Pritami, A.A., Soemarwoto, R.A.S., Wintoko, R., 2022. Faktor Risiko Kanker Paru : Tinjauan Pustaka. *J. Agromedicine* 9, 120–123.

Puspita, D., Astuti, V.D., Sampurno, E., 2022. Karakteristik Mutasi EGFR pada

- Pasien Kanker Paru Jenis Adenokarsinoma yang Diterapi dengan TKI di Rumah Sakit Paru Dr . H . A Rotinsulu Bandung. *Sanus Med. J.* 1;1-4, 2020–2023. <https://doi.org/10.22236/sanus.v3i1.8431>
- Putriani, F.A., Kholis, F.N., Purwoko, Y., 2019. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi Egfr Dan Non Mutasi Egfr. *Diponegoro Med. J. (Jurnal Kedokt. Diponegoro)* 8, 214–221.
- Reynaldi, A., Trisyani W, Y., Adiningsih, D., 2020. Kualitas Hidup Pasien Kanker Paru Stadium Lanjut. *Jnc* 3, 71–79.
- Ridwanuloh, A.M., 2016. Menengok Peran Pemeriksaan Mutasi Gen Bagi Penderita Kanker Paru. *Biotrends* 7, 5–8.
- Sharma, S. V., Bell, D.W., Settleman, J., Haber, D.A., 2007. Epidermal growth factor receptor mutations in lung cancer. *Nat. Rev. Cancer* 7, 169–181. <https://doi.org/10.1038/nrc2088>
- Sulviana, E.R., Kurniasari, L., 2021. Hubungan Antara Usia, Pendidikan, dan Pekerjaan dengan Kejadian Kanker Payudara pada Wanita di Kalimantan Timur. *Borneo Student Res.* 2, 1937–1943.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71, 209–249. <https://doi.org/10.3322/caac.21660>
- Sutandyo, N., Hanafi, A., Jayusman, M., 2019. Comparison of effectiveness of gefitinib, erlotinib, and afatinib in advanced non-small cell lung cancer patients with EGFR mutation positive in indonesian population. *Chinese J. Lung Cancer* 22, 562–567. <https://doi.org/10.3779/j.issn.1009-3419.2019.09.02>
- Syahrudin, E., Wulandari, L., Muktiati, N.S., Rima, A., Soeroso, N., Ermayanti, S., Levi, M., Hidajat, H., Widjajahakim, G., Utomo, A.R.H., 2018. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed indonesian lung cancer patients. *Lung Cancer Targets Ther.* 9, 25–34.

<https://doi.org/10.2147/LCTT.S154116>

Tezel, G.G., Şener, E., Aydın, Ç., Önder, S., 2017. Prevalence of epidermal growth factor receptor mutations in patients with non-small cell lung cancer in Turkish population. *Balkan Med. J.* 34, 567–571. <https://doi.org/10.4274/balkanmedj.2017.0297>

Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., Matsuo, K., Mitsudomi, T., 2012. Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung Cancer* 78, 207–211. <https://doi.org/10.1016/j.lungcan.2012.09.006>

Wang, Y., Huang, K., Sun, S., Deng, Y., Xie, X., 2022. Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer. *Risk Manag. Healthc. Policy* 15, 351–359. <https://doi.org/10.2147/RMHP.S352827>

Wu, J.Y., Wu, S.G., Yang, C.H., Chang, Y.L., Chang, Y.C., Hsu, Y.C., Shih, J.Y., Yang, P.C., 2011. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. *Lung Cancer* 72, 205–212. <https://doi.org/10.1016/j.lungcan.2010.08.013>

Wulandari, F., Utami, W., Rohana, E., Prabhata, W.R., 2021. Efikasi Terapi Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKIs) pada Kanker Paru. *J. Res. Pharm.* 1, 25–33.

Yang, Z., Hackshaw, A., Feng, Q., Fu, X., Zhang, Y., Mao, C., Tang, J., 2017. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. *Int. J. Cancer* 140, 2805–2819. <https://doi.org/10.1002/ijc.30691>

You, J.H.S., Cho, W.C.S., Ming, W.K., Li, Y.C., Kwan, C.K., Au, K.H., Au, J.S.K., 2021. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. *PLoS One* 16, 1–14. <https://doi.org/10.1371/journal.pone.0247860>

Yulianti, S., 2010. Faktor-Faktor yang Berhubungan dengan Kejadian Kanker

Payudara di RSUP DR. Wahidin Sudirohusodo Makassar 1–89.

Zaini J, Syahrudin E, Andarini SL, 2018. Kanker paru karsinoma bukan sel kecil. Buku ajar pulmonologi dan Kedokt. respirasi 9–22.

Zheng, M., 2016. Classification and Pathology of Lung Cancer. Surg. Oncol. Clin. N. Am. 25, 447–468. <https://doi.org/10.1016/j.soc.2016.02.003>

Zhu, J., He, W., Ye, M., Fu, J., Chu, Y.B., Zhao, Y.Y., Zhang, Y.J., Kuo, D., Wu, B., 2018. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. *Futur. Oncol.* 14, 2833–2840. <https://doi.org/10.2217/fon-2018-0321>

